Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA ( (FR:IPH) ) just unveiled an update.
Innate Pharma S.A., a clinical-stage biotechnology company specializing in cancer immunotherapies, develops differentiated next-generation antibody drugs such as IPH4502, lacutamab and monalizumab. The group operates from Marseille and Rockville and is dual-listed in Paris and on Nasdaq, supported by collaborations with major pharmaceutical companies and research institutions.
On May 6, 2026, Innate Pharma announced it would host a conference call and webcast on May 13, 2026, to present its business progress for the first quarter of 2026. The planned event, led by the chief executive and other senior executives, underscores continuing investor communication around the status of its oncology pipeline and financial position, with a replay to be made available online for stakeholders unable to join live.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging antibody-engineering and novel target identification, it is advancing a pipeline of next-generation antibody therapeutics, including IPH4502 for solid tumors, lacutamab for T cell lymphomas and monalizumab for non-small cell lung cancer, often in partnership with major pharma and academic institutions.
Headquartered in Marseille with a U.S. office in Rockville, the company is listed on Euronext Paris and Nasdaq, and collaborates with groups such as Sanofi and AstraZeneca to strengthen its position in immuno-oncology. Its portfolio targets areas of high unmet medical need, seeking potential first- or best-in-class status for several assets in development.
Average Trading Volume: 284,423
Technical Sentiment Signal: Sell
Current Market Cap: €117M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.